We have used chromium dioxide magnetic particles as the solid support in developing a series of immunological tests. The high surface area (>40 m2/g) available on the magnetic particles and their easy dispersion throughout a solution allow for rapid and complete capture of the target antigen. The magnetic responsiveness of the particles allows for rapid, high-efficiency washing to reduce nonspecific binding, which often limits the sensitivity of serological assays. These features form the basis of extremely rapid and flexible assays for several hormones and markers of cancer and infectious disease. Most of the assays involve monoclonal antibodies. Here we describe specific performance characteristics for thyroxin, follitropin, creatine kinase isoenzyme MB, and antibody to human immunodeficiency virus (HIV). All of the assays are performed in <90 mm, many in 30 to 45 mm. The technology is highly flexible and is suitable for a variety of formats, from manual to fully automated. coupled with its expanding biotechnology capabilities through developing monoclonal antibodies and conjugates, has supplied the foundation for our development of novel magnetic particle-based immunoassays.
and washing.
Du Pont's experience in the development and manufacture of chromium dioxide for magnetic recording tape (3), coupled with its expanding biotechnology capabilities through developing monoclonal antibodies and conjugates, has supplied the foundation for our development of novel magnetic particle-based immunoassays.
In addition to the above-mentioned advantages, chromium dioxide particles have the following properties: rapid separation and resuspension characteristics; low remnant magnetism with minimal magnetic aggregation; wettability; stability in aqueous solutions; and a functional, derivatized surface for the covalent attachment of antigens and antibodies. The magnetic, physical, and stability properties of chro- mium dioxide particles for magnetic tapes have been significantly altered to provide assay-quality particles. These particles, approximately 5 zm in diameter, have a specific surface area of >40 m2/g ( Figure 1 ) and exhibit a proteinuptake capacity of approximately 40 mg per gram of solids. Antibodies selected for high affinity and specificity are attached to the chromium dioxide particles and are used in one-site competitive-binding and two-site immunometric assays. In one-site competitive-binding assays, which are intended to measure small molecules (e.g., thyroxin, T4), labeled analyte is incubated with the sample containing the analyte, and with a limited amount of antibody attached to chromium dioxide particles.2 After a short incubation, during which analyte and the labeled analyte compete for the limited antibody-binding sites on the particles, a magnetic field is directed at the reaction mixture, causing the particles to aggregate. The supernate is removed and the chromium dioxide particles are washed several times, by alternating magnetic separations and resuspensions.
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After the final wash, the labeled analyte bound to the particles is measured and used to calculate the concentration of analyte in the original sample.
The two-site approach is intended to measure large molecules with multiple binding sites, e.g., follitropin (FSH) and markers of infectious disease. In this case, the sample is incubated, either sequentially or simultaneously, with antibody attached to chromium dioxide particles and with a second,labeled antibody. During the incubation period, the first antibody captures the analyte and binds it to the chromium dioxide particles, while the secondantibody binds Fig. 1 . Photornicrographof chromium dioxide particles to the captured analyte, thus labeling it. After the incubation, the particles are separated magnetically and washed to remove excess antibody and serum interferences. After reincubation with a marker for the label, the particles are separated magnetically and the marker or label is measured in the supernate. The amount of marker present, which is related to the amount of label retained on the particles, is directly proportional to the analyte concentration in the original sample.
In a third approach, immunoenzymometric assays, a monoclonal antibody, highly specific for an enzyme or analyte (e.g., creatine kinase, CK-MB), is used. The antibody is covalently attached to chromium dioxide particles and specifically captures MB from the sample. After the capture-incubation step, the mixture is magnetically separated and washed. The washed particles, containing MB, are then incubated with a CK substrate reagent. After a final magnetic separation, the supernate is removed and analyzed for the amount of product produced, which, over a fixed-time interval, is directly proportional to the CK-MB activity of the original sample.
Here we document the flexibility of the chromium dioxide-based immunoassay technology by reporting results for the applications described above.
Materials and Methods

Materials
Instrumentation.
We used manual pipettes-SMI Digital Adjust Micro/Pettor, For these studies we obtained fresh human serum samples and stored them frozen at -20 #{176}C or -70 #{176}C.
Preparatory Procedure
Monoclonal antibodies. Balb/c mice were immunized with follitropin or lutropin to obtain the alpha-specific or betaspecific clones. Spleen lymphocytes were fused with P3-NS1 lAg4 mouse myeloma cells by using polyethylene glycol according to the protocol of Fazekas de St. Groth and Scheidegger (4). The resulting clones were initially screened by ELISA, then by an RIA with iodinated FSH (Du Pont NEN Products).
Clones were recloned and injected intraperitoneally into pristane-primed Balb/c mice. We purified the ascites on a Protein A-Sepharose 4B column, eluting the bound antibodies with sodium citrate buffer (50 mmol/L, pH 3.0). The monoclonal anti-CK-MB antibody was obtained from Washington University School of Medicine, St. Louis, MO 63110.
Polyclonal antibodies. The antibodies to human IgG and T4 were raised in goat and rabbit, respectively (Cambridge Medical Technology, Billerica, MA 01865).
Alkaline phosphatase-conjugated antibodies. We reacted 5 mg of alkaline phosphatase (EC 3. The reaction mixture was purified on a 1.0 x 30 cm Sephadex 0-25 column by ehuting with the same PBS buffer. The maleimide-alkaline phosphatase and SH-IgG fractions were combined and incubated at room temperature for 60 mm. We then added 10 pL of 100 mmol/L 2-mercaptoethylamine (Sigma Chemical Co.) reagent and incubated the reaction mixture for 20 mm at room temperature. The reaction mixture was purified on a 2.15 x 25 cm Dii Pont Bio Series GF 250 XL column, eluted at a flow rate of 2 mL/min with "TBS" buffer (10 mmol of Tris and 172 mmol of NaC1 per liter, pH 8.5).
Alkaline phosphatase-conjugated T4. Conjugates were prepared by reacting 5. 
Assay Procedures
Total T4 assay. Add 10 1zLof sample, calibrator, or control to 40 ML of the T4-releasing reagent, 25 pL of chromium dioxide particles coated with anti-T4 antibodies and 100 i.tL of alkaline phosphatase-conjugated T4; incubate for 30 mm at 37 #{176}C. Separate the reaction mixture magnetically, then wash once with 250 ML and twice with 500 ML of the wash buffer. After the final wash, resuspend the particles and incubate in 500 pL of substrate solution (p-nitrophenyl phosphate) for 30 mm at 37 #{176}C. Again separate the particles magnetically, aspirate the supernate into the flow cell, and measure the absorbance at 403 nm. We used a logit-log function to convert the absorbance reading to T concentration.
FSH assay. 
Results
Assay Characteristics
Antigen capture. A monoclonal antibody with high specificity and affinity for prostatic acid phosphatase was immobilized on both chromium dioxide particles and 6-mmdiameter polystyrene beads. The amount of sample antigen captured from the solution phase onto the solid support (chromium dioxide particles or polystyrene bead) was measured as a function of capture-incubation time, by using substrate (p-nitrophenyl phosphate) to measure the activity of the captured antigen. As shown in Figure 2 , 90% of the sample antigen was captured in the first 3 mm of the incubation with chromium dioxide particles. A substantially smaller percentage (<20%) had been captured by the polystyrene bead in 10 mm. Furthermore, total capture by the bead was not complete until >20 h. The responsiveness of chromium dioxide particles to magnetic aggregation and resuspension was measured turbidimetrically. As shown in Figure 3 , the particles exhibit excellent responsiveness to magnetic aggregation and resuspension, typically completing the entire processof separation and complete resuspension in <2 mm.
Stability of chromium dioxide particles. Hydrolytic stability, as determined by measuring chromate leaching vs time, of the magnetic tape particles and assay-quality particles is shown in Figure 4 . Although the magnetic particles are highly unstable in solution, the specially coated assayquality particles are stable for >14 days at 37 #{176}C and have demonstrated a shelf-life of more than one year at 4#{176}C.
Specific Assays
Total T4 assay. Standard curves exhibited an analytical range through 200 g/L. The minimum detectable concentration of T4, as determined by a nonpaired Student's t-test vs the zero calibrator (95% confidence interval), was 8.0 g/ L in this assay. Analytical recovery was measured in 10 random sera by adding T4, 20.2 g/L, to each sample. The mean analytical recovery was 105.3% (range 100-112%). Within-assay precision (CV) for T4 in serum-based controls (Lyphochek#{174}; Bio Rad ECS Division, Anaheim, CA 92806) ranged from 2.4% to 3.5% at 171.0 and 50.3 g/L, respectively (Table 1) . Parallelism was determined by diluting each of five sera (T4 >160 g/L) with the zero calibrator. Each of the serum dilution curves are superimposable on the standard curve, demonstrating excellent parallelism. The T4 assay correlated well (r = 0.946) with a widely used RIA method (NML Tetra Tab#{174}; Nuclear Medical Laboratories, Irving, TX 75015) and exhibited the following regression statistics: slope 1.021, intercept 6.9 g/L, and standard
FSH assay. Standard CK-MB assay. Standard curves exhibited an analytical range through 200 UJL, based on the micromolar conversion of NAD to NADH. The minimum detectable concentration of CK-MB, as determined above, was 4 UIL. Within-assay precision (CV) for CK-MB in serum-based controls (CK-1; Cala Diagnostics, Los Osos, CA 93402) and pooled sera ranged from 3.0% to 4.6% at 176.5 and 27.6 UIL, respectively. Between-assay precision (CV) for assays of the same materials ranged from 3.0% to 5.2% at 180.9 and 26.8 U/L, respectively (Table 1) NW-antibody assay. Serum and plasma samples, obtained from individuals known to be seropositive for IUV, were serially diluted fivefold with either serum or plasma from a single seronegative donor. As shown in Figure 5 , the chromium dioxide particle assay yields similar results for plasma collected in commonly used anticoagulants and for serum. Moreover, the chromium dioxide assay is at least as sensitive as the microtiter plate HTLV ifi ELISA assay (Du Pont Specialty Diagnostics, Wilmington, DE 19898), as determined with serum or plasma samples obtained from 43 individuals known to be seropositive for H1V and from 252 normal donors. Both assays showed complete sample-tosample agreement for seropositive and negative samples. As Figure 6 shows, the chromium dioxide particle assay clearly distinguishes the HIV-antibody-positive and normal populations.
Discussion
The use of chromium dioxide particles as a solid support allowed us to develop very sensitive and rapid immunoassays. Chromium dioxide particles offer a much larger surface area than can be achieved with the more common solid supports, such as 6-mm-diameter polystyrene beads, coated tubes, and microtiter plates. Each assay typically involves 50 to 250 tg of chromium dioxide particles.
The greater surface area represented by this amount of chromium dioxide allows more immobilized antibody to be presented to the sample. Because the capture mechanism is a bi-moleculas reaction, the law of mass action dictates that the kinetics of the reaction will be faster when the concentration of one or both of the reactants is increased. The capture kinetics are further enhanced, with immobilized species, when the solid phase can be intimately mixed throughout the solution, thus reducing the mean path of diffusion of the individual reactants. The final result is a faster turnaround of test results, e.g., <30 win for FSH and <60 win for detecting H1V antibody.
The special coating applied to magnetic-tape chromium dioxide particles serves several purposes in the production of assay-quality particles. First, it prevents chromate leaching and improves hydrolytic stability. Second, it produces a surface that can be easily modified to reduce nonspecific binding. Finally, it improves the surface for the covalent coupling of antigens and antibodies; this improves the stability of the assays and yields a high protein-uptake capacity. . Distributionof results for normal donors and AIDS population, relativeto cutofffor chromium dioxide particle prototype assay
The magnetic responsiveness of chromium dioxide particles offers optimal utility in solid-phase immunoassays. Although they are ferromagnetic, the particles exhibit low remnant magnetism, thus allowing repeated separation and resuspension for incubation, washing, and measurement steps. The ability to optimally wash the particles, along with ease of modifying the surface, is responsible for low nonspecific binding and minimal matrix effects. These characteristics account for the excellent parallelism and recovery exhibited by each of the assays.
We addressed the practical consideration of pipetting chromium dioxide particle slurries by using a variety of techniques in these studies. We used both manual pipets and semiautomated, commercially available, pipetting devices with comparable success, as reflected in the precision of these results. In addition, we used this technology with both spectrophotometric and fluorometric detection. These results suggest that the technology is highly flexible and applicable to a variety of assay formats, from manual to fully automated.
In summary, we have demonstrated a wide range of applications for the chromium dioxide particle technology, including assays for CK-MB, hormones, and markers of infectious disease. Good precision and accuracy, exemplified by excellent recovery, parallelism, and correlation, were demonstrated in assay times that represent a fraction of the time required by other isotopic or nonisotopic methods for these analytes.
